Dyanavel XR Approved for ADHD
October 20, 2015 – The U.S. Food and Drug Administration approved Dyanavel XR (extended-release oral suspension of amphetamine), manufactured by Tris Pharmaceuticals. Dyanavel XR is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children at least six years old and includes both immediate-release and extended-release amphetamine made possible through its proprietary process. This process allowed for effectiveness that could start within an hour and last approximately 13 hours during clinical testing. Dyanavel XR is dispensed in bottles containing 464mL (about 15.5 ounces) with 2.5mg of amphetamine per mL, as well as an oral syringe marked accurately in mL increments. Recommended dosing for children beginning treatment with Dyanavel XR is 2.5mL or 5mL each morning; and may be increased up to 20mg per day if ADHD is not managed by lower doses. Dyanavel XR is a schedule II controlled substance and includes a boxed warning that it could be subject to abuse and patients on it may develop dependency. Pricing information for Dyanavel XR is currently unavailable. Tris Pharmaceuticals plans to launch Dyanavel XR in 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.